Purpose: Dyspnea is highly prevalent in lung cancer survivors following curative-intent therapy. We aimed to identify clinical predictors or determinants of dyspnea and characterize its relationship with functional exercise capacity (EC). Methods: In an analysis of data from a cross-sectional study of lung cancer survivors at the VA San Diego Healthcare System who completed curative-intent therapy for stage I-IIIA disease ≥ 1 mo previously, we tested a thorough list of comorbidities, lung function, and lung cancer characteristics. We assessed dyspnea using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (LC13) and functional EC using the 6-minute walk. We replicated results with the University of California San Diego Shortness of Breath Questionnaire. Results: In 75 participants at a median of 12 mo since treatment completion, the mean ± SD LC13-Dyspnea score was 35.3 ± 26.2; 60% had abnormally high dyspnea. In multivariable linear regression analyses, signifi cant clinical predictors or determinants of dyspnea were ( β [95% CI]) psychiatric illness ( − 20.8 [ − 32.4 to − 9.09]), heart failure with reduced ejection fraction ( − 15.5 [ − 28.0 to − 2.97]), and forced expiratory volume in the fi rst second of expiration ( − 0.28 [ − 0.49 to − 0.06]). Dyspnea was an independent predictor of functional EC ( − 1.54 [ − 2.43 to − 0.64]). These results were similar with the University of California San Diego Shortness of Breath Questionnaire. Conclusion: We identifi ed clinical predictors or determinants of dyspnea that have pathophysiological bases. Dyspnea was independently associated with functional EC. These results have implications in efforts to reduce dyspnea and improve exercise behavior and functional EC in lung cancer survivors following curative-intent therapy.
E xercise has been shown to be effective in improving function and quality of life (QoL) 1 and is recommended by the American College of Sports Medicine 2 and the American Cancer Society 3 for many cancer survivors. However, the evidence of effectiveness is not as consistent in lung cancer survivors. 4 This inconsistency may be related to characteristics unique to lung compared with other cancer survivors, including differences in age, comorbidities, and the effects of lung cancer and its treatment on exercise capacity (EC). Many patients with lung cancer are elderly and have major comorbidities that include chronic obstructive pulmonary disease (COPD) and heart failure that may limit EC. 5 Also, curative-intent therapy of lung cancer necessitates the removal and/or destruction of lung tissue, which may further exacerbate symptoms and impede cardiopulmonary function and EC in some patients.
Symptom burden may limit exercise in lung cancer survivors. Following lung cancer resection surgery, dyspnea worsens 6 partly due to a loss of 10-15% of lung function. 7 Clinically signifi cant dyspnea has been shown to be prevalent in > 50% of lung cancer survivors. [8] [9] [10] [11] As a result, lung cancer survivors may avoid exercise to prevent dyspnea. In time, this avoidance can lead to a downward spiral of health related to physical function, symptom burden, and QoL (see Supplemental Digital Content 1, available at: http://links.lww.com/JCRP/A132 ), all of which are important survivorship issues in lung cancer. 12 Therefore, the characterization of dyspnea in lung cancer survivors may provide important insights into factors associated with dyspnea and may facilitate interventions to improve exercise, function, and QoL in these patients.
The purpose of this project was to identify clinical predictors or determinants of dyspnea in lung cancer survivors following curative-intent therapy and analyze the relationship between dyspnea and functional EC. It is believed that optimization of underlying comorbidities including cardiopulmonary disease may be important in improving exercise, function, and QoL in these patients.
METHODS
In a previous cross-sectional study to assess functional EC and patient-reported outcomes in lung cancer survivors following curative-intent therapy, exploratory patient-reported outcomes assessments identifi ed abnormally high dyspnea in ≈ 60% of participants 13 as assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (LC13). 14 In this study, additional participants were enrolled to identify clinical predictors or determinants of dyspnea and explore its relationship with functional EC. Guideline recommendations for Strengthening the Reporting of Observational studies in Epidemiology were used to report fi ndings. 15 The VA San Diego Healthcare System (VASDHS) Institutional Review Board approved this protocol (#H150158).
At the VASDHS, all patients diagnosed with primary or progressive/recurrent lung cancer are presented to a weekly multidisciplinary chest tumor board for management planning. From a list of consecutive patients presented at the VASDHS chest tumor board, kept to ensure quality clinical care, potentially eligible patients were identifi ed. Between August 2016 and April 2018, consecutive patients were recruited by informational letters mailed to those whose lung cancer was diagnosed and/or managed at the VASDHS since October 2010. Follow-up occurred with a maximum of 3 telephone calls 1 wk later to gauge interests and written informed consent was obtained from all participants. Previously, 87% of all eligible patients were enrolled using this recruitment method. 13 This study included lung cancer survivors with pathologic and presumed lung cancer diagnoses (ie, those with lung nodules deemed by the chest tumor board to have high pre-test probability for lung cancer but at high risk for severe complications from tissue biopsy) who completed lung cancer resection surgery, defi nitive radiation, or concurrent chemoradiation for stage I-IIIA disease ≥ 1 mo previously. The study excluded patients who had progressive/recurrent lung cancer or were unable to follow directions and/or physically perform functional EC evaluation: severe dementia, bilateral below-knee amputation, or quadriplegia, and active systemic treatment for other cancers. A thorough list of clinical variables related to lung cancer and/or cardiopulmonary health were collected using data from the electronic health records. These included age, sex, body mass index, tobacco exposure, comorbidities (including COPD, heart failure with reduced ejection fraction [HFrEF], psychiatric illness), lung function (forced expiratory volume in the fi rst second of expiration [FEV 1 ], diffusion of the lung for carbon monoxide, total lung capacity), and echocardiographic fi ndings where available. Chronic obstructive pulmonary disease was defi ned as clinical documentation of COPD by a pulmonologist and/or postbronchodilator FEV 1 /forced vital capacity < 0.7 on spirometry, HFrEF as clinical documentation of systolic heart failure or echocardiographic ejection fraction ≤ 50%, and psychiatric illness as anxiety, depression, or post-traumatic stress disorder documented by a psychiatrist and/or active prescriptions of anxiolytics or antidepressants. Lung cancer characteristics included clinical stage and treatment modality. Time since treatment completion was also included to assess the possible effects of treatment or recovery on outcomes. All data were collected by a board-certifi ed physician with subspecialty training in pulmonology (D.H.).
DYSPNEA ASSESSMENTS
Dyspnea was assessed using the LC13 14 and the University of California San Diego Shortness of Breath Questionnaire (SOBQ). 16 The LC13-Dyspnea score was used for primary analyses due to previous validation in the lung cancer population. 14 The LC13 is a 13-item questionnaire designed to assess lung cancer-associated symptoms (cough, dyspnea, hemoptysis, and pain) and chemo-and radiotherapy side effects (dysphagia, hair loss, neuropathy, sore mouth); dyspnea is assessed by 3 items on perceived shortness of breath at rest, when walking, and climbing stairs, scored as a mean of the component items with raw score range of 0 to 100. 14 Abnormally high dyspnea was defi ned as LC13-Dyspnea scores greater than mean reference value. 17 The SOBQ was used to replicate fi ndings. The SOBQ is a 24-item questionnaire designed to assess self-reported shortness of breath with a variety of activities of daily living in patients with chronic lung disease 16 that has previously been used in lung cancer survivors 13 , 18 ; responses are summed to a score range of 0 to 120. 16 In both the L13 and SOBQ questionnaires, higher scores indicate a higher level of perceived dyspnea. All questionnaire assessments were performed at the same time on printed forms without any modifi cations and prior to functional EC testing.
FUNCTIONAL EC
The primary outcome was functional EC as assessed by the 6-minute walk test, performed according to the standard protocol recommended by the American Thoracic Society Pulmonary Function Standards Committee. 19 In lung cancer survivors, the 6-min walk test distance (6MWD) has been validated against the gold standard of cardiopulmonary fi tness (maximal EC, maximal or peak oxygen uptake) (concurrent validity), 20 shown to decrease with treatment (responsiveness), 21 shown to be low compared with general age-, sex-, height-, and weight-matched adults (discriminant validity), 13 and was independently associated with cancer-specifi c QoL (predictive validity). 13 
STATISTICAL ANALYSES
Descriptive statistics were summarized as appropriate; both L13-Dyspnea and SOBQ scores were analyzed as continuous variables. Univariable (UVA) and multivariable (MVA) linear regressions were used to analyze the relationship between all collected clinical characteristics and identify predictors or determinants of dyspnea and analyze the relationship between dyspnea and functional EC.
For MVAs, stepwise, backward selection modeling was used, starting with all variables with P < .10 in UVAs; those with the largest P values were sequentially eliminated from the models until all remaining variables were associated with the dependent variable (dyspnea or functional EC) at P < .10. Results were interpreted using regression coefficients ( β ), 95% CI, and coeffi cients of determination ( R 2 and partial R 2 ), and statistical signifi cance was defi ned as P < .05 in 2-tailed tests. All data were managed with RED-Cap electronic data capture tools 22 hosted at the local institution and analyzed as available without imputation using IBM SPSS Statistics software versions 25 and 26.
RESULTS
This study enrolled 75 lung cancer survivors at a median of 12 mo since completing curative-intent therapy. Their baseline clinical characteristics are described in Table 1 . Most were white males with a history of tobacco use, concomitant COPD, and underwent either lung cancer resection surgery or defi nitive radioablation for the treatment of stage I non-small cell lung cancer (NSCLC).
DYSPNEA AND FUNCTIONAL EC
All participants completed dyspnea and 6MWD assessments. The LC13-Dyspnea and SOBQ scores were 35.3 ± 26.2 and 34.8 ± 25.6, respectively. These scores correlated very well ( r = 0.84, P < .001) (see Supplemental Digital Content 2, available at: http://links.lww.com/JCRP/ A133 ). Forty-fi ve participants (60%) had abnormally high dyspnea, defi ned as LC13-Dyspnea raw score greater than mean reference value for patients with lung cancer (29.5). 17 The 6MWD was 347.9 ± 124.2 m (67% of predicted values in healthy adults 23 ) ( Table 1 ) . Figure 1A and B). 
PREDICTORS OR DETERMINANTS OF DYSPNEA

Dyspnea Is an Independent Predictor of Functional EC
Results of UVAs to identify predictors of functional EC are shown in Table 3 . In MVAs starting with all baseline clinical characteristics borderline signifi cantly associated with functional EC, dyspnea was found to be an independent predictor of functional EC ( − 1.54 [ − 2.43 to − 0.64] for each point ) ( Table 4 ; Figure 2A ). These results were replicated by the SOBQ ( − 1.70 [ − 2.62 to − 0.78]) ( Table 4 ; Figure 2B ).
DISCUSSION
In an analysis of data from a cross-sectional study of veteran lung cancer survivors following curative-intent therapy, this study found abnormally high dyspnea in most patients and identifi ed 3 important clinical predictors or determinants of dyspnea: psychiatric illness (anxiety/depression/ post-traumatic stress disorder), HFrEF, and physiological measure of obstructive ventilatory defect (FEV 1 ). In addition, dyspnea was an independent predictor of functional EC and accounted for 14-16% of its variance. These results highlight the importance of dyspnea in early-stage lung cancer survivorship and have implications for interventions aimed at improving exercise, function, and QoL in these patients.
The Institute of Medicine emphasizes the fundamental importance of care in the post-treatment phase of cancer survivorship, including supportive services to promote health and reduce long-term and late treatment effects. 24 Exercise is recommended by the American College of Sports Medicine 2 and the American Cancer Society 3 for many cancer survivors to promote health and reduce functional and QoL impairments. These recommendations are based on evidence of effectiveness in breast, prostate, and colon cancer survivors [25] [26] [27] ; however, this evidence is not as consistent in lung cancer survivors. 4 Recent systematic reviews of exercise interventions in lung cancer survivors suggest that while exercise training as part of rehabilitation programs can improve functional EC and QoL following curative-intent therapy, [28] [29] [30] [31] concerns for selection bias and inadequate sample size exist. 28 , 29 , 32 Moreover, a recent systematic review identifi ed numerous patient-related barriers to regular exercise in lung cancer survivors. 33 These include physical capacity, symptoms, comorbidities, previous sedentary lifestyle, and psychological infl uences. 33 Lung cancer survivors are different from other cancer populations due to a higher median age at diagnosis, lifetime exposure to tobacco, and prevalence of pulmonary and cardiovascular comorbidities. 5 The median age at lung cancer diagnosis is 70 yr. 34 Most of lung cancer cases are caused by cigarette smoking, 35 which has many adverse health consequences. The most common comorbidities in patients with lung cancer, all of which can progressively and negatively impact health, are COPD, 36 , 37 diabetes, and heart failure, prevalent in 50-70%, 16%, and 13% of patients, respectively. 5 In addition, the effects of curative-intent therapy of lung cancer have unique effects on cardiopulmonary health since part of the therapy requires local destruction and/or removal of lung tissue, which may exacerbate symptoms and impede function and EC in some patients, making typical exercise interventions inaccessible. 31 The characterization of dyspnea may provide important insights into strategies to effectively improve exercise in this group of cancer survivors. The mechanisms of dyspnea are incompletely understood 38 ; however, peripheral sensors including through refl ex chemoreceptor stimulation by carbon dioxide, pulmonary vagal C-fi bers, mechanoreceptors, and central pathways (specifi cally the limbic system and sensorimotor Covariates selected to enter model ( P < .1): age, hyperlipidemia, coronary artery disease, forced expiratory volume in the first second of expiration (FEV 1 ) % predicted, DL CO % predicted, adenocarcinoma, and treatment group ( Table 3 ). c Overall model R 2 = 0.46, P < .001; no significant interaction between age and SOBQ ( P = .995), or DL CO % predicted and SOBQ ( P = .55).
cortex) are thought to play important roles. 38 In lung cancer survivors following curative-intent therapy, dyspnea can be made worse due to a loss of 10-15% of lung function from lobectomy. 39 In addition, other possible pathophysiological effects may include a loss of associated nerve fi bers and peripheral sensors due to the removal and/or destruction of lung tissue by surgery and/or radiotherapy. Adjuvant chemotherapy has been shown to cause peripheral neuropathy 40 and, therefore, possibly also vagal perturbations. These effects may accumulatively result in neuromechanical dissociation, which is implicated in the pathogenesis of dyspnea. 41 Importantly, dyspnea was independently associated with functional EC in this study. For each 1-point increase in baseline dyspnea score, there was a 1.5-to 1.7-m decrease in the 6MWD. The association between dyspnea and functional EC has been described in other patient populations including COPD. 42 To the best of our knowledge, this relationship has not been previously characterized in lung cancer survivors following curative-intent therapy, many of whom experience worsening of dyspnea 6 as laid out previously. Moreover, a previous analysis of 359 postsurgical, stage I NSCLC survivors showed that dyspnea was signifi cantly associated with physical health. 10 In fact, of all the variables included in that study, 10 dyspnea had approximately twice the effect size ( β ) on physical health as the next 2 largest effect sizes (employment status and depression symptoms). Another study also confi rmed this large effect size of dyspnea on physical health. 43 These fi ndings suggest that alleviating dyspnea may be a key factor to improve exercise in these patients.
The prevalence of abnormally high dyspnea in the current study (60%) is similar to previous reports in lung cancer survivors following curative-intent therapy. [8] [9] [10] [11] In 1 study, 8 the prevalence of COPD (23%) was signifi cantly lower (75%), while the prevalence of abnormal/clinically signifi cant dyspnea was the same. In that study, 65% dyspneic patients reported not having dyspnea preoperatively, suggesting treatment-related effects. 8 Moreover, LC13 dyspnea scores were reported to be higher in 830 post-surgical lung cancer survivors than in propensity-matched individuals from the general population, particularly in those with cardiac or pulmonary comorbidity and in those treated with combined modality therapy. 44 Results in the current study showed an association between treatment type and dyspnea scores only in univariable (see Supplemental Digital Content 3, available at: http://links.lww.com/JCRP/ A134 ) but not in multivariable ( Table 2 ) analyses, possibly The predictors or determinants of dyspnea identifi ed offer complimentary information to a previous report in 342 post-surgical NSCLC survivors 8 and another in 142 longterm, post-surgical NSCLC survivors. 43 In addition, HFrEF and psychiatric illness were identifi ed as predictors or determinants, which have clinical management implications in these patients.
This study has novel insights. Historically, most lung cancer cases were diagnosed at advanced stages and treated with palliation. However, the landscape for lung cancer is changing rapidly 45 due to advances in screening, 46 , 47 diagnostic, 48 and therapeutic 49 , 50 modalities. As the number of earlier-stage lung cancer survivors increases, 51 , 52 more attention must be paid to the unique health challenges faced by this group of cancer survivors. 12 A prospective study was recently completed which showed that dyspnea symptoms worsen at 1 to 3 mo following curative-intent lung cancer treatment. 53 As such, it is postulated that in order to maximize efforts to improve exercise, function, and QoL in lung cancer survivors following curative-intent treatment, optimizing medical therapy for cardiopulmonary disease 54 and possibly psychiatric illness 55 to alleviate dyspnea may also be important. Recent randomized controlled trials in patients with COPD have shown that combination long-acting muscarinic-antagonist and β -agonist inhaler therapy is effective in reducing dyspnea 56 and, possibly, in improving physical activity. 57 , 58 Initiation of combination long-acting muscarinic-antagonist and β -agonist bronchodilators, particularly in survivors with concomitant COPD, may be an important fi rst step. Moreover, while exercise training as part of comprehensive rehabilitation programs may improve function and QoL in lung cancer survivors, studies in patients with chronic lung disease show that the benefi ts of exercise training wane over time, as patients do not increase or maintain activity outside the training setting. 59 A recent systematic review of exercise programs in lung cancer survivors identifi ed the need for home-based exercise programs, 31 reported by many cancer survivors to be more desirable. 60 In addition, traditional exercise interventions focus on moderate to vigorous intensity exercise. More recently, light-intensity exercise and sedentary behavior are also recognized as important in health promotion: the US Department of Health & Human Services emphasized that moving more and sitting less will benefi t nearly everyone. 61 Therefore, in addition to reducing dyspnea, exercise interventions in lung cancer survivors may need to also promote light-intensity exercise and reduce sedentary behavior to be effective (see Supplemental Digital Content 1, available at: http://links.lww.com/JCRP/A132 ).
This study has limitations. First, despite a thorough list of important clinical characteristics in the lung cancer population, only 30-40% of the variances in dyspnea scores were explained. However, to the best of our knowledge, no other studies have reported higher R 2 values including those reported in a large, international, population-based study involving 9484 participants with many demographic and clinical variables (largest R 2 reported = 0.13). 62 Second, the cross-sectional and descriptive nature of this study provides no insight on the effects of lung cancer treatment on dyspnea, the underlying physiobiological mechanism, or how to effectively alleviate it; information on medical therapy for comorbidities was not collected, limiting the ability to draw conclusions between medical therapy and dyspnea scores. Third, these fi ndings may have limited generalizability due to it being a single-institutional study involving a predominantly white male veteran patient population with significant tobacco exposure and higher prevalence of COPD and psychiatric illness. 5 Fourth, lung function (FEV 1 ) but not a spirometric diagnosis of COPD was associated with dyspnea in this study, which may be due to the small sample size and/or a limitation in data containing both pre-and post-treatment lung function. Fifth, in this study, 35% of lung cancer survivors had coronary artery disease, 40% had previous history of other cancers, and 79% of those who had undergone echocardiography had diastolic dysfunction, all of which could additionally impact dyspnea. These variables were not signifi cantly associated with dyspnea, possibly due to a small sample size.
The strengths of this study include a detailed list of comorbidities and physiological measures of cardiopulmonary health including lung function, all of which were entered in the electronic medical record and collected by board-certifi ed physicians, maximizing the accuracy of the data obtained. In addition, all patient reported outcome and functional EC assessments were performed in-person by 1 observer (D.H.), maximizing the completeness and accuracy of the data collected and minimizing interobserver variability. Finally, the fi ndings were verifi ed using a second dyspnea questionnaire, maximizing the validity of the conclusions.
In conclusion, abnormally high dyspnea was prevalent in ≥ 50% of lung cancer survivors following curative-intent therapy, partly due to underlying psychiatric illness, presence of HFrEF, and obstructive ventilatory defects. In addition, dyspnea was a signifi cant independent predictor of functional EC. Efforts to improve exercise, function, and QoL in lung cancer survivors may need to also focus on optimizing therapy for comorbid cardiopulmonary and/or psychiatric illnesses and reduce dyspnea to be effective.
